Researchers push U.S. DEA to let them grow pot

May 24, 2007

Researchers are pressing the U.S. Drug Enforcement Administration to allow them to grow marijuana for research purposes.

The researchers, who claim a recent DEA administrative law judge's ruling that it would be in "the public interest" to allow marijuana to be grown for study vindicates their cause, said samples of the plant grown by the government are difficult to obtain and of poor quality, The Washington Post reported Thursday.

"The DEA has an opportunity here to live up to its rhetoric, which has been that marijuana advocates should work on conducting research rather than filing lawsuits," said Richard Doblin, president of the Multidisciplinary Association for Psychedelic Studies, which has been fighting to test possible medical uses of marijuana for years.

"It's become more and more obvious that the DEA has been obstructing potentially beneficial medical research, and now is the time for them to change," he told the Post.

Copyright 2007 by United Press International

Explore further: New drug sales help boost Novartis Q1 profit (Update)

add to favorites email to friend print save as pdf

Related Stories

SK Hynix posts Q1 surge in net profit

29 minutes ago

South Korea's SK Hynix Inc said Thursday its first-quarter net profit surged nearly 350 percent from the previous year on a spike in sales of PC memory chips.

FCC to propose pay-for-priority Internet standards

29 minutes ago

The Federal Communications Commission is set to propose new open Internet rules that would allow content companies to pay for faster delivery over the so-called "last mile" connection to people's homes.

Brazil enacts Internet 'Bill of Rights'

49 minutes ago

Brazil's president signed into law on Wednesday a "Bill of Rights" for the digital age that aims to protect online privacy and promote the Internet as a public utility by barring telecommunications companies ...

Zynga founder Pincus leaving operations role

11 hours ago

Online game maker Zynga says company founder Mark Pincus is stepping down as chief product officer, less than a year after he was replaced as the company's CEO.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

New breast cancer imaging method promising

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Breast cancer replicates brain development process

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Research proves nanobubbles are superstable

The intense research interest in surface nanobubbles arises from their potential applications in microfluidics and the scientific challenge for controlling their fundamental physical properties. One of the ...

Using antineutrinos to monitor nuclear reactors

When monitoring nuclear reactors, the International Atomic Energy Agency has to rely on input given by the operators. In the future, antineutrino detectors may provide an additional option for monitoring. ...